Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Allarity Therapeutics, Inc. - Common stock (NQ:ALLR)

1.180 +0.050 (+4.42%)
Streaming Delayed Price Updated: 3:13 PM EDT, Jul 14, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 97,213
Open 1.150
Bid (Size) 1.160 (200)
Ask (Size) 1.200 (500)
Prev. Close 1.130
Today's Range 1.115 - 1.210
52wk Range 0.7687 - 2.350
Shares Outstanding 365,173,471
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Allarity Therapeutics Announces CLIA Certification, Clearing the Path for Advancing DRP® Testing for FDA Registration
From Allarity Therapeutics, Inc.
Via GlobeNewswire
News headline image
Allarity Therapeutics Announces the Grant of Essential U.S. Patent for Its Stenoparib DRP® Companion Diagnostic
From Allarity Therapeutics, Inc.
Via GlobeNewswire

Performance

YTD
+3.5%
+3.5%
1 Month
-20.3%
-20.3%
3 Month
-0.8%
-0.8%
6 Month
+3.5%
+3.5%
1 Year
+12.4%
+12.4%

More News

Read More
News headline image
Allarity Therapeutics to Present Trial-in-Progress Poster on Phase 2 Stenoparib Trial at ESMO Gynaecological Cancers Congress 2026
From Allarity Therapeutics, Inc.
Via GlobeNewswire
News headline image
Allarity Therapeutics Reports First Quarter 2026 Results and Continued Stenoparib Development in Multiple Cancers
From Allarity Therapeutics, Inc.
Via GlobeNewswire
News headline image
Allarity Therapeutics CEO to Present at Precision Medicine Forum Europe 2026 in Stockholm
From Allarity Therapeutics, Inc.
Via GlobeNewswire
Why Did Allarity Therapeutics Stock Double In Value Today? ↗
Via Stocktwits
News headline image
Allarity Therapeutics Advances Stenoparib Toward Pivotal Development with Phase 3 Manufacturing Campaign
From Allarity Therapeutics, Inc.
Via GlobeNewswire
News headline image
Allarity Therapeutics Announces that the Stenoparib DRP® Test Has Received a Notice of Allowance from the US Patent and Trademark Office
From Allarity Therapeutics, Inc.
Via GlobeNewswire
News headline image
Allarity Therapeutics Presents Two AACR 2026 Posters Highlighting Stenoparib’s Potential in Colorectal Cancer as well as New Predictive Data Linking DRP® and Overall Survival in Ovarian Cancer
From Allarity Therapeutics, Inc.
Via GlobeNewswire
News headline image
Allarity Therapeutics Reports Full Year 2025 Financial Results and Corporate Progress
From Allarity Therapeutics, Inc.
Via GlobeNewswire
News headline image
Allarity Therapeutics Closes $20 Million Financing to Accelerate the Advance of Stenoparib Toward FDA Approval and Commercialization
From Allarity Therapeutics, Inc.
Via GlobeNewswire
News headline image
Allarity Therapeutics Doses First Patients in VA-Funded Phase 2 Trial Focused on Small Cell Lung Cancer with High Unmet Need
From Allarity Therapeutics, Inc.
Via GlobeNewswire
News headline image
Allarity Therapeutics announces that its collaborative Phase 2 trial with the United States Veteran’s Administration Combining Stenoparib with Temozolomide in Relapsed Small Cell Lung Cancer is Now Open for Enrollment
From Allarity Therapeutics, Inc.
Via GlobeNewswire
News headline image
Allarity Therapeutics Issues 2025 End of Year CEO Letter to Shareholders
From Allarity Therapeutics, Inc.
Via GlobeNewswire
News headline image
Allarity Therapeutics Provides Third Quarter 2025 Financial Results and Provides Business Updates
From Allarity Therapeutics, Inc.
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Monday's Intraday Session ↗
Via Benzinga
News headline image
Allarity Therapeutics Presents New Phase 2 Clinical Data for Stenoparib/2X-121 Showing Landmark Median Overall Survival Has Now Surpassed 25 Months
From Allarity Therapeutics, Inc.
Via GlobeNewswire
News headline image
Allarity Therapeutics CEO to Present at Biomarkers & Precision Medicine 2025
From Allarity Therapeutics, Inc.
Via GlobeNewswire
News headline image
These stocks have an unusual volume in today's session ↗
Via Chartmill
News headline image
12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗
Via Benzinga
News headline image
Top stock movements in today's session. ↗
Via Chartmill
News headline image
Check out the stocks that are attracting the most attention and driving market activity. ↗
Via Chartmill
News headline image
Power Metallic’s (TSX-V: PNPN | OTCQB: PNPNF) Strategic Appointment Signals Major Paradigm Shift Ahead – More Stocks Inside
Via AB Newswire
Topics Government
News headline image
12 Health Care Stocks Moving In Tuesday's Intraday Session ↗
Via Benzinga
News headline image
Tuesday's session: top gainers and losers ↗
Via Chartmill

Frequently Asked Questions

Is Allarity Therapeutics, Inc. - Common stock publicly traded?
Yes, Allarity Therapeutics, Inc. - Common stock is publicly traded.
What exchange does Allarity Therapeutics, Inc. - Common stock trade on?
Allarity Therapeutics, Inc. - Common stock trades on the Nasdaq Stock Market
What is the ticker symbol for Allarity Therapeutics, Inc. - Common stock?
The ticker symbol for Allarity Therapeutics, Inc. - Common stock is ALLR on the Nasdaq Stock Market
What is the current price of Allarity Therapeutics, Inc. - Common stock?
The current price of Allarity Therapeutics, Inc. - Common stock is 1.180
When was Allarity Therapeutics, Inc. - Common stock last traded?
The last trade of Allarity Therapeutics, Inc. - Common stock was at 07/14/26 03:13 PM ET
What is the market capitalization of Allarity Therapeutics, Inc. - Common stock?
The market capitalization of Allarity Therapeutics, Inc. - Common stock is 430.90M
How many shares of Allarity Therapeutics, Inc. - Common stock are outstanding?
Allarity Therapeutics, Inc. - Common stock has 431M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.